WEE1 and endometrial cancer: To delineate the mechanisms underlying the impact of WEE1 inhibitors on endometrial cancer, we treated HEC-1-A, HEC-1-B, ISHIKAWA, RL95-2, and KLE cell lines with different concentrations of AZD1775 for 72 h.